CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 108 target
Drug / intervention
Envafolimab+Lenvatinib +1 moredrug
Likely dose
Envafolimab+Lenvatinib 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05112991
NCT05112991Phase 2RecruitingOn TrackUpdated 3mo ago
Long Recruiting
CompareCT.gov

An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

3D Medicines (Sichuan) Co., Ltd.·interventional·Posted Nov 9, 2021·Updated Mar 25, 2026

In Brief

A Phase 2 clinical trial evaluating Envafolimab+Lenvatinib and Envafolimab for Advanced Endometrial Cancer. Currently recruiting, targeting 108 participants across 19 sites.

Detailed Summary

This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Endometrial Cancer
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
202220232024202520262027
First PostedNov 9, 2021
Enrollment StartMar 4, 2022
Primary CompletionDec 1, 2026
TodayJul 1, 2026
Enrollment to primary: 4.7 yearsPosted 4.6 years agoPrimary completion in 5 months

Interventions

Envafolimab+Lenvatinibdrug

Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle. Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle.

Envafolimabdrug

Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.